PART 5: The Longevity and Brain Peptides

MOTS-c, Semax, Selank, Epitalon, KPV and DSIP: Can a Peptide Really Make You Live Longer—or Think Better?

The bigger the promise, the stronger the evidence should be. Unfortunately, in the longevity peptide world, the opposite often seems to be true.

By Alex Foxman, MD, FACP, ABOM

Double Board-Certified in Internal Medicine and Obesity Medicine

Founder, Beverly Hills Institute

“Doc, is there a peptide that can slow aging?”

This may be the ultimate peptide question.

Once we move beyond injury recovery, muscle and weight loss, the claims become even bigger:

More energy. Better memory. Improved sleep. Less inflammation. Healthier mitochondria. Slower cellular aging. A longer life.

MOTS-c, Semax, Selank, Epitalon, KPV and DSIP are increasingly promoted under the broad umbrella of longevity, brain health and anti-aging medicine.

Some have fascinating biology.

Some have intriguing animal rese.

A few have been used or studied outside the United States.

But when we ask the question that has guided this entire series

What has actually been proven in humans?

The story becomes much less exciting.

MOTS-c: The “Exercise Mimetic” Peptide

MOTS-c may be one of the most scientifically interesting peptides in this series.

It is unusual because it is encoded within mitochondrial DNA. Researchers first described it in 2015, and laboratory and animal studies suggest that it may influence glucose metabolism, fat metabolism, cellular stress responses and energy regulation.

In mice, synthetic MOTS-c has been associated with reduced diet-induced obesity and improved insulin sensitivity.

That has led to dramatic marketing claims:

• Improves metabolism

• Burns fat

• Increases exercise performance

• Protects against aging

• Improves mitochondrial function

• Extends healthspan

  
  

It sounds almost like exercise in a syringe.

Unfortunately:

Humans are not mice.

FDA reviewers found no published studies in which compounded MOTS-c products were administered to humans and no adequate human exposure data from which to determine safety. FDA specifically continues to list MOTS-c among substances for which it lacks sufficient information to know whether administration to humans may cause harm.

That doesn't mean MOTS-c will ultimately fail.

It means we are still near the beginning of the story.

But Didn't the FDA Advisory Committee Just Vote for MOTS-c?

Yes—and this is where patients need to understand the regulatory language.

In July 2026, the FDA Pharmacy Compounding Advisory Committee recommended that MOTS-c be added to the 503A Bulks List, potentially allowing qualifying pharmacies to compound it under specific circumstances. The same committee also supported several other controversial peptides.

But FDA's own scientific reviewers had recommended against including MOTS-c because of the lack of human effectiveness and safety information.

The committee recommendation is nonbinding, and it is not FDA approval.

It does not mean MOTS-c has been shown to treat obesity.

It does not mean it improves longevity.

And it certainly does not mean it has been demonstrated to extend human life.

Access and evidence are two completely different questions.

Epitalon: Can We Manipulate Aging Itself?

Epitalon may have one of the boldest reputations in the peptide world.

It is promoted for:

• Anti-aging

• Telomere support

• Improved sleep

• Melatonin regulation

• Immune function

• Increased lifespan

  
  

Much of the excitement comes from older preclinical work and reports suggesting effects on the pineal gland, telomerase activity and lifespan in laboratory models.

But the leap from changing a cellular process to making a human live longer is enormous.

At its July 2026 meeting, FDA specifically evaluated Epitalon for insomnia, not as a longevity therapy. FDA scientific staff recommended against adding it to the 503A Bulks List. The agency states that it has not identified adequate safety information for the proposed route of administration and has concerns involving peptide aggregation, impurities and potential immune reactions.

The advisory committee nevertheless narrowly recommended its inclusion for compounding.

Again:

A vote allowing possible compounding is not proof that Epitalon slows human aging.

We currently do not have large, rigorous, long-term randomized trials demonstrating that Epitalon extends human lifespan or prevents age-related disease.

Semax: A “Nootropic” Peptide for the Brain

Semax is frequently promoted as a cognitive-enhancing or “neuroprotective” peptide.

Claims include:

• Improved memory

• Better concentration

• Reduced anxiety

• Stroke recovery

• Neuroprotection

• Increased BDNF

• Improved mental performance

  
  

Semax has a history of medical use and investigation in Russia and some other countries, particularly in neurologic conditions.

But international use is not the same as FDA approval.

At the July 2026 meeting, FDA evaluated Semax for cerebral ischemia, migraine and trigeminal neuralgia. FDA staff again recommended against inclusion on the 503A Bulks List, citing insufficient evidence and limited safety information for proposed compounded routes.

The advisory committee ultimately recommended Semax for inclusion.

FDA nevertheless continues to state that compounded Semax may pose immunogenicity risks because of aggregation and peptide-related impurities, and that human safety information remains limited.

This is where the same rule from Part 1 applies:

A biological effect in the brain is not the same as improved cognition in a healthy human being.

Increasing BDNF or affecting neurotransmitter pathways may be scientifically interesting.

It does not prove that taking Semax will make you smarter or prevent dementia.

Selank: The Anti-Anxiety Peptide

Selank is often mentioned alongside Semax.

It is marketed for:

• Anxiety reduction

• Stress resilience

• Improved focus

• Better mood

• Cognitive performance

  
  

Unlike Semax, Selank was not one of the peptides reviewed at the July 2026 advisory committee meeting.

However, FDA currently lists Selank acetate among substances for which important human safety information is lacking and identifies potential concerns involving peptide aggregation, impurities and immunogenicity.

There are published studies from Russia and surrounding regions, but the evidence base does not resemble the large, multicenter randomized trials we would expect before recommending a drug broadly for anxiety or cognitive enhancement in healthy Americans.

For now, I would consider Selank investigational—not established neuropsychiatric medicine.

KPV: The Tiny Anti-Inflammatory Peptide

KPV is a three-amino-acid fragment associated with alpha-melanocyte-stimulating hormone.

It is promoted for:

• Gut inflammation

• Skin disease

• Autoimmune conditions

• Wound healing

• “Systemic inflammation”

  
  

There is interesting laboratory evidence suggesting anti-inflammatory activity.

But as of the FDA's latest review, the agency reported that it had identified no human exposure data for drug products containing KPV through any route of administration.

Yet the July 2026 advisory committee recommended it for inclusion on the 503A Bulks List.

That provides perhaps the clearest example of the distinction we have discussed throughout this series:

A regulatory recommendation does not manufacture missing clinical data.

KPV may ultimately become useful.

Today, we simply do not have enough human evidence to know.

DSIP: The “Sleep Peptide”

Delta sleep-inducing peptide—now referred to by FDA as emideltide—has been marketed for years for:

• Insomnia

• Deeper sleep

• Stress reduction

• Pain

• Opioid withdrawal

• Hormonal regulation

  
  

Its name alone is great marketing.

Who doesn't want a peptide called “delta sleep-inducing peptide” if they cannot sleep?

But names do not determine effectiveness.

At the July 2026 advisory meeting, FDA reviewed emideltide for opioid withdrawal, chronic insomnia and narcolepsy. FDA staff recommended against inclusion on the compounding list because adequate effectiveness and safety evidence were lacking.

Unlike MOTS-c, Semax, KPV and Epitalon, the advisory committee did not recommend emideltide/DSIP for inclusion.

FDA also states that it has not identified adequate safety information for the proposed administration route.

For a substance promoted for decades, that should make patients stop and ask:

If this is such an effective sleep treatment, where are the convincing modern human trials?

What About Thymosin Alpha-1?

Thymosin alpha-1 deserves its own category.

It has been studied internationally for immune modulation and is approved for certain indications in some countries, but it is not an FDA-approved drug in the United States.

It is promoted domestically for immune “boosting,” infection resistance and longevity.

But more immune activity is not necessarily better immune function.

The immune system needs regulation, not simply stimulation.

FDA currently states that available safety information for compounded thymosin alpha-1 is inadequate to fully characterize potential risks and notes concerns involving immunogenicity and peptide-related impurities.

The Biggest Problem With “Longevity” Claims

If someone tells me a drug helps pain, we may be able to test pain.

If someone tells me a drug lowers cholesterol, we can measure cholesterol.

But if someone claims:

“This peptide slows aging.”

The scientific burden becomes enormous.

Does it reduce heart attacks?

Cancer?

Dementia?

Frailty?

Disability?

Mortality?

Does it improve healthspan rather than simply alter a laboratory marker?

And how many years were people followed?

Changing a biomarker associated with aging is not the same as slowing human aging.

Telomeres are not longevity.

Mitochondrial signaling is not longevity.

A higher BDNF level is not dementia prevention.

Reduced inflammation in a mouse is not proof that a human will live longer.

These may be clues.

They are not answers.

My Physician Verdict

MOTS-c

One of the more scientifically intriguing experimental peptides, particularly from a metabolic and mitochondrial standpoint. But there is not yet adequate human clinical evidence to recommend it for obesity, performance or longevity.

Semax

Interesting neurologic pharmacology and international experience, but insufficient high-quality evidence for routine cognitive enhancement or brain-health use in healthy adults.

Selank

Interesting but investigational. Not enough high-quality human evidence for routine anxiety or cognitive treatment.

Epitalon

Longevity claims dramatically exceed the evidence. There is no convincing evidence that it extends human lifespan.

KPV

Interesting anti-inflammatory biology, but essentially absent meaningful human exposure data.

DSIP / Emideltide

An appealing concept with an appealing name—but inadequate modern clinical evidence to recommend it as an established sleep treatment.

Thymosin alpha-1

A biologically active immunomodulator with legitimate research history, but current U.S. wellness and longevity claims go beyond established FDA-approved medicine.

So After Five Parts, What Do I Actually Think About Peptides?

I began this series with the question patients ask me almost every day:

“Doc, what do you think about peptides?”

My answer after reviewing the science is the same—but more nuanced.

Peptides are not the problem. Bad evidence is.

Some peptide medications have revolutionized medicine.

Insulin saves lives.

Modern incretin therapies have transformed obesity and diabetes treatment.

Other peptide medications have proven indications in osteoporosis, endocrinology and other diseases.

And many experimental peptides deserve serious scientific investigation.

But something troubling has happened.

The commercial peptide market has begun treating the beginning of scientific discovery as though it were the end.

A mouse study becomes a treatment.

A mechanism becomes a promise.

A biomarker becomes “longevity.”

A podcast becomes informed consent.

And a regulatory discussion about compounding becomes “FDA approved” on social media.

That is not how medicine should work.

My Rule Is Simple

I am willing to be early on promising science.

I am not willing to be ahead of the evidence when my patient's safety is involved.

Innovation and evidence-based medicine are not enemies.

The best medicine requires both.

We should absolutely investigate MOTS-c.

Study BPC-157 properly.

Determine whether Semax has meaningful neurologic applications.

Explore peptide therapies for metabolic disease, inflammation, tissue repair and aging.

But do the trials.

Measure the outcomes.

Follow patients long enough.

Monitor the complications.

And then let the evidence—not the algorithm—tell us what works.

The future of peptide medicine may be extraordinary.

But the future should arrive through science.

Not through hype.

Evidence over hype. Science over social media. Patient safety first.

— Alex Foxman, MD, FACP, ABOM

Double Board-Certified in Internal Medicine & Obesity Medicine

Beverly Hills Institute

Regulatory information reviewed through August 17, 2026. FDA advisory committee recommendations discussed above are nonbinding and should not be interpreted as FDA drug approval. This article is intended for general educational purposes and does not constitute individualized medical advice.